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A new anticancer agent based on the conjugation of a 
photoactivatable Pt(IV) pro-drug to a cyclic RGD-containing 
peptide is described. Upon visible light irradiation, 
phototoxicity was induced preferentially in SK-MEL-28 10 
melanoma cancer cells overexpressing αVβ3 integrin 
compared to control DU-145 human prostate carcinoma cells. 
The use of visible light has enormous potential in chemotherapy 
for controlling, at a desired time, the place and dose, and release 
of cytotoxic species from inert anticancer pro-drugs. For this 15 
reason, much efforts has been dedicated to the development of 
photoactivatable metal-based anticancer complexes for improving 
drug efficacy and reducing toxic side-effects associated with 
platinum-based chemotherapeutic drugs currently used in the 
clinic.1 In addition, photoactivation offers the possibility for new 20 
mechanisms of action as well as the formation of novel adducts 
with the final biological target (not only DNA, but also RNA or 
proteins), which are important variables to overcome inherent or 
acquired resistance to cisplatin. Among photoactivated 
metallodrugs, Pt(IV) diazidodihydroxido complexes are 25 
particularly promising since they are inert and nontoxic in the 
dark, but become highly active against a range of cancer cell lines 
upon irradiation with visible light, including cisplatin-resistant 
cells (A2780cis).2 Such Pt(IV) pro-drugs accumulate in tumour 
cells and bind strongly to DNA by generating adducts distinct 30 
from those of cisplatin.3 Ru(II) arene complexes such as [(η6-p-
cym)Ru(bpm)(py)]2+ or its peptide derivatives can also be 
activated by visible light to induce the dissociation of the Ru-
pyridine bond and the generation of an active species with 
capacity to react with DNA.4 A similar pro-drug approach has 35 
been described with some Ru polypyridyl complexes masked 
with thioether groups that can be removed selectively upon 
visible light irradiation.5 Very recently, caging groups have also 
been applied to control the activity of Ru(II) and Re(I) 
complexes.6  40 
 Despite these promising examples, it is desirable to improve 
some of the pharmacological properties of photoactivatable 
metallodrugs, such as aqueous solubility and cell uptake, as well 
as higher selectivity against cancer cells. In this context, targeted 
approaches based on peptide vectors whose receptors are 45 
overexpressed on cancer cells in combination with light 
activation can be used to develop anticancer agents with a double 
mechanism of selectivity, such as the conjugates between a 
photoactivatable Ru(II) arene complex and receptor-binding 
peptides recently described by us4b or a conjugate between a 50 
caged Re(I) organometallic complex and bombesin.6b  
 Herein we report the conjugation of a photoactivatable Pt(IV) 
pro-drug, trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1)2 (Fig. 1), to a 
cyclic peptide containing the RGD sequence (-Arg-Gly-Asp-), 
which is selectively recognized by αVβ3 and αVβ5 integrins. The 55 
overexpression of these transmembrane heterodimeric 
glycoproteins in different tumor cells together with their known 
relationship with tumor angiogenesis, which is an essential 
process for tumor growth and metastasis, make them relevant 
targets in medicinal chemistry.7 In fact, RGD-containing peptides 60 
have been exploited extensively for tumour imaging and for 
targeted drug delivery of cytotoxic compounds,8 including some 
metal-based anticancer drugs.4b,9 As recently found by us for 
conjugates between a Pt(IV) derivative of picoplatin and RGD-
containing peptides,9d we hypothesize that the peptide vector will 65 
confer complex 1 with selectivity for cancer cells overexpressing 
pro-angiogenic integrins such as αVβ3 and αVβ5. The novelty of 
this approach resides in the use of a photoactivatable Pt(IV) pro-
drug since irradiation with visible light directly within the tumour 
will trigger the release of cytotoxic Pt(II) species from the 70 
internalized conjugate (3 in Fig. 1), thus providing a Pt(IV)-based 
anticancer agent with a dual control over selectivity. 
 
Fig. 1 Structure of trans,trans,trans-[Pt(N3)2(OH)2(py)2] (1), 
trans,trans,trans-[Pt(N3)2(OH)(succ)(py)2] (2) and schematic 75 
representation of the Pt-c(RGDfK) conjugate (3). 
 First, one of the axial hydroxyl groups of complex 1 was 
esterified with succinic anhydride to generate trans,trans,trans-
[Pt(N3)2(OH)(succ)(py)2] (2) (Fig. 1),10 which contains a 
carboxylic acid function suitable for attaching the peptide moiety. 80 
As shown in Fig. 2, we selected as a carrier the cyclic 
pentapeptide c(RGDfK),11 which is a conjugatable version of 
Cilengitide, c(RGDf[N-Me]V), an antagonist of pro-angiogenic 
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and currently in clinical phase III trials for the 
treatment of patients with brain tumors.12 The incorporation of 
non-natural D-Phe and [N-Me]-Val in the cyclic structure is 
responsible for increasing both the stability in biological fluids 
and the higher selectivity for αVβ3 integrin over αVβ5 and α5β1.12b 5 
In our case, replacement of N-methyl Val by Lys allowed further 
derivatization of the RGD-containing peptide with a 
polyethyleneglycol spacer at the ε-NH2 function. Then, complex 
2 was attached to peptide intermediate 49d by using HATU in the 
presence of DIPEA in anhydrous DMF for 2 h at RT in the dark. 10 
The expected Pt-c(RGDfK) conjugate (3) was obtained as a pale 
yellow solid (54% yield) after purification by reversed-phase 
HPLC and lyophilisation (Fig. S1, ESI†). Conjugate 3 was 
unambiguously characterized by high-resolution ESI mass 
spectrometry and 1H NMR spectroscopy. As shown in Fig. 3 and 15 
Fig. S2 (ESI†), a m/z value consistent with the calculated value of 
the charged species ([M+H]+) and with the expected isotopic 
mass distribution pattern of Pt was obtained. In addition, 
diagnostic signals from the platinum complex (pyridine ligands) 
and from the peptide moiety (amide NH protons and aromatic 20 
protons of D-Phe) in the aromatic region of the 1H NMR spectra 
confirmed the covalent attachment of the Pt complex to the 
peptide vector (Fig 3 and Fig S3, ESI†). 
 
Fig. 2 Schematic representation of the synthesis of the Pt-c(RGDfK) 25 
conjugate (3) and of the photo-reaction with 5’-GMP. 
 Next, the efficiency of the photoactivation of Pt-c(RGDfK) 
conjugate (3) in the presence of 5’-GMP (2 mol equiv.) was 
investigated by HPLC-MS. As shown in Fig. S4 (ESI†), 
irradiation (λirr= 420 nm, 11 mW cm-2, 45 min, 37ºC) led to the 30 
complete disappearance of 3 and to the formation of a major 
species that was characterized by HR-ESI-MS as the Pt(II)-GMP 
adduct, trans-[Pt(N3)(5-GMP)(py)2]+ (6 in Fig. 2) (GMP is 
considered neutral in all the formulae). In addition, two minor 
GMP adducts were identified, trans-[Pt(py)2(5’-GMP)2]2+ and 35 
[Pt2(N3)(py)4(5’-GMP)]+. The photodissociation of conjugate 3 to 
form the Pt(II)-GMP adduct as a major product, parallels the 
behaviour observed for the parent complexes 12a and 210, 
indicating that the attached peptide does not alter the 
photochemical properties or the type of photoadducts with a 40 
model nucleobase. Furthermore, the release of the intact 
succinate-c(RGDfK) moiety (5 in Fig. 2), implies that the carrier 
ligand neither competes with 5’-GMP for binding to the 
photoreleased Pt(II) species, nor does it form any secondary 
reactions, being a simple targeting vector of the Pt(IV) pro-drug. 45 
 
Fig. 3 1H NMR spectra of conjugate 3 (A) in H2O/D2O 9:1, showing the 
region between 6.7 and 9.1 ppm. Expanded HR ESI mass spectrum of the 
molecular peak of 3 ([M+H]+), calculated (B) and experimental (C). 
 Having established the photoactivation properties of the Pt-50 
c(RGDfK) conjugate, our next objective was to investigate its 
toxicity towards different cancer cell lines in the presence of 
visible light to assess the capacity of the peptide vector to deliver 
the photoactivatable Pt(IV) pro-drug into cancer cells 
overexpressing integrin receptors. On the basis of flow cytometry 55 
studies (Fig. 4), we selected SK-MEL-28 human malignant 
melanoma cell line as a model to evaluate the phototoxicity of 3 
since it expresses high levels of αVβ3 integrin compared with 
αVβ5 integrin (mean cell fluorescence intensity of 217.4 and 23.3 
for αVβ3 and αVβ5 integrins, respectively).9d As negative control, 60 
the DU-145 human prostate carcinoma cell line was selected 
since the expression of αVβ3 integrin was considerably lower, 
whereas that of αVβ5 integrin was similar (mean cell fluorescence 
intensity of 16.6 and 31.8 for αVβ3 and αVβ5 integrins, 
respectively). As expected, the internalization of the fluorescein-65 
labelled RGD-containing peptide, Fluo-c(RGDfK) (7),9d was 
slightly higher in the αVβ3 integrin overexpressing SK-MEL-28 
cells than in DU-145 (by 1.6-fold when incubated at 10 µM; see 
Fig. S5, ESI†), which points to the active participation of this 
integrin receptor in the uptake of the peptide.  70 
 The photocytotoxicity of the Pt-c(RGDfK) conjugate (3) and 
of the parent Pt complexes (1 and 2) was determined upon 
irradiation with visible light (λirr= 420 nm, 5 J/cm2) in both cell 
lines. The photoactivated dose-dependent inhibition of cell 
viability for compounds 1-3 towards SK-MEL-28 and DU-145 75 
cells and their phototoxic indices are summarised in Table 1 and 
the cytotoxicity plots are shown in Fig. S6 (ESI†). First, it is 
worth noting that the IC50 value for complex 1 in SK-MEL-28 
was similar to those previously found in other cancer cell lines 
(IC50 = 6.8 µM in HaCaT, 8.3 µM in A2780 or 8.4 µM in OE19, 80 
under blue light irradiation),2b although the cytotoxicity in DU-
145 cells was about 4-fold lower than in the melanoma cancer 
cell line. Hence, these results confirm the high antitumour 
efficiency of this Pt(IV) pro-drug against cancer cells of different 
origin when photoactivated with visible light. Second, the 85 
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cytotoxic effect of 1 was slightly reduced in SK-MEL-28 (about 
1.5-fold) upon derivatization with a succinate group (2). This 
tendency was not reproduced in DU-145, since the cytotoxic 
effect was increased upon succinylation (IC50 =20 µM for 2 vs 
IC50 =43 µM for 1).  5 
 
Fig. 4 Expression of αVβ3 and αVβ5 integrins in SK-MEL-28, DU-145  
and MDA-MB-468 cell lines. Representative flow cytometry histograms 
obtained after the indirect immunofluorescence staining. Solid lines 
represent the fluorescence intensity of the cells after the incubation with 10 
monoclonal antibodies against both integrins followed by the incubation 
with secondary antibody conjugated to Alexa-Fluor 488. Dotted lines 
indicate the background staining with the secondary antibody alone. 
As shown in Table 1, the phototoxicity of conjugate 3 in SK-
MEL-28 (IC50 = 19.5 µM) was similar to that of the parent 15 
succinylated complex 2 (IC50 = 15.5 µM), whereas the 
differences in the irradiated mean IC50 values were higher in DU-
145 cells (IC50 = 20 µM for 2 and 54 µM for 3). This result is in 
good agreement with the levels of expression of the αVβ3 integrin 
and with the cellular uptake experiments with the fluorescein-20 
labelled peptide, and is consistent with the participation of the 
receptor in the biological activity of the conjugate. Hence, 
conjugation to the RGD-containing peptide vector seems to 
confer selectivity to complex 2 since the anticancer activity is 
higher in the melanoma cancer cell line that overexpresses αVβ3 25 
integrin receptor whereas a lower phototoxicity was found in the 
human prostate cancer cell line. This difference was increased 
when conjugate 3 was irradiated with UVA (λirr= 365 nm, 5 
J/cm2) in both cell lines. Interestingly, DU-145 cells treated with 
aminolaevulinic acid (ALA) using the same blue light source 30 
were twice as susceptible than SK-MEL-28 cells (irradiated mean 
IC50 values = 0.12 mM and 0.23 mM, respectively). Thus, the 
melanoma cancer cells were more resistant to the porphyrin-
based therapy, but more sensitive to the Pt-based therapy 
compared to the prostate cancer cells. 35 
Table 1 IC50 values of 5 J/cm2 visible light or UVA irradiated human DU-
145 and SK-MEL-28 cells pretreated with compounds 1-3. 
  SK-MEL-28  DU-145  
  IC50a (µM) PIb IC50a (µM) PIb 
1 420 nm 10.2 (7.9-13.0) 20.8 43.2 (33.0-56.6) 4.9 
2 420 nm 15.5 (10.2-23.6) 11.3 20.0 (14.7-27.3) 8.8 
3 420 nm 19.5 (13.4-28.2) 3.6 53.9 Wide 1.3 
3 365 nm 9.9 (9.5-10.1) 8 56.4 (50.9-61.9) 2.7 
aIC50 is defined as the concentration of compound that inhibits dye uptake by 50%. 
The lowest value indicates the highest toxicity to cells. bPI: Phototoxic index. 
 Since the cellular uptake of the Pt-peptide conjugate depends 40 
both on the level of expression of the pro-angiogenic integrins 
and on the binding affinity of the RGD-containing peptide 
towards these receptors, the determination of the intracellular 
accumulation is of high importance to assess the effect of the 
peptide conjugation on the biological activity of the Pt(IV) pro-45 
drug as well as to investigate the contribution of each integrin 
subtype. For this purpose, in addition to SK-MEL-28 and DU-
145 cells, we selected the MBA-MD-468 breast adenocarcinoma 
cell line as positive control for αVβ5 integrin. As shown in Fig. 4, 
the expression of αVβ5 integrin was considerably higher than that 50 
of αVβ3 integrin (mean cell fluorescence intensity of 3.8 and 42.4 
for αVβ3 and αVβ5 integrins, respectively). Then, the three cancer 
cell lines were exposed to 10 µM solutions of compounds 1-3 in 
the dark for 1 h, and the intracellular level of platinum was 
quantified by inductively-coupled plasma mass spectrometry 55 
(ICP-MS). 
As shown in Fig. 5, the accumulation of platinum after exposure 
of the three cell lines to Pt-c(RGDfK) conjugate (3) (46.6 + 2 
pmol Pt/106 cells in DU-145, 130.7 + 9 pmol Pt/106 cells in SK-
MEL-28 and 166.5 + 6 pmol Pt/106 cells in MBA-MD-468) was 60 
higher than that of complex 1 (26.2 + 2.4 pmol Pt/106 cells in 
DU-145, 72.6 + 1.9 pmol Pt/106 cells in SK-MEL-28 and 73.6 + 
2 pmol Pt/106 cells in MBA-MD-468) or 2 (15.9 + 2.7 pmol 
Pt/106 cells in DU-145, 75.4 + 9.6 pmol Pt/106 cells in SK-MEL-
28 and 86.8 + 7 pmol Pt/106 cells in MBA-MD-468). This clearly 65 
indicates that peptide conjugation has a positive effect on the 
intracellular accumulation of the photoactivatable Pt(IV) pro-
drug. Notably, platinum accumulation in SK-MEL-28 cells after 
exposure to conjugate 3 was higher (about 2.8-fold) than in DU-
145 cells, which agrees with the higher expression of αVβ3 70 
integrin in the human malignant melanoma cell line compared 
with the prostate carcinoma cell line, as well as with the 
internalization studies with the fluorescein-labelled peptide. 
 
Fig. 5 Cell accumulation of platinum in SK-MEL-28, DU-145 and MBA-75 
MD-468 cells after exposure to compounds 1-3 (10 µM, dark, 1 h). The 
platinum content is related to the cell number. Errors bars represent the 
standard deviation of three replicates. 
To our surprise, the intracellular accumulation of 3 in MBA-MD-
468 was also higher than in DU-145 cells (about 3.6-fold) despite 80 
the very low expression of αVβ3 integrin in the breast carcinoma 
cell line. This result and the fact that accumulation of 3 in MBA-
MD-468 was about 1.3-fold higher than in SK-MEL-28 points 
out to the internalization of the Pt-c(RGDfK) conjugate mediated 
by αVβ5 integrin as well. These results are in agreement with the 85 
known selectivity of RGD-containing peptides, particularly the 
cyclic version c(RGDfK), for cancer cells overexpressing αVβ3 
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and αVβ5 integrins and suggest in all cases the participation of the 
peptide in the internalization of the conjugate. The reduced 
selectivity of conjugate 3 for αVβ3 integrin compared with 
Cilengitide can be attributed to the replacement of [N-Me]-Val by 
the Lys residue where the photoactivatable Pt(IV) complex is 5 
attached. Hence, on the basis of the overall results, we can 
envisage the integrin-mediated internalization and accumulation 
of the intact Pt-peptide conjugate in cancer cells overexpressing 
αVβ3 and/or αVβ5 integrins, where it will be photoactivated to 
generate cytotoxic Pt(II) species with capacity to react with 10 
nucleic acids, as inferred by the adduct generated with 5’-GMP. 
Otherwise, a premature activation of the Pt(IV) pro-drug or 
hydrolysis of the conjugate would lead to similar or even lower Pt 
accumulation ratios than those obtained with control complexes. 
Interestingly, a correlation was found between intracellular 15 
accumulation of conjugate 3 and phototoxicity (see Table 1): a 
lower IC50 value upon visible light irradiation and a higher 
phototoxic index was found in the melanoma cancer cells that 
accumulated a higher amount of the compound compared with 
prostate carcinoma cells. Notably, the accumulation of 1 and 2 in 20 
SK-MEL-28 and MBA-MD-468 cells was also higher than in 
DU-145, thereby revealing a preference for the melanoma and 
breast cancer cells. It is also interesting that despite the higher 
accumulation of conjugate 3 compared with the parent 
complexes, the phototoxicity was slightly reduced, particularly 25 
when comparing with 1 in SK-MEL-28. This might be 
attributable to differences in the quantum yield of the compounds 
and to the accumulation of the conjugate in intracellular vesicles 
that might interfere with the interaction of the released Pt(II) 
species with the target. 30 
 In conclusion, our results demonstrate the potential of 
conjugating photoactivatable metal complexes, such as Pt(IV) 
pro-drugs, to peptides with the aim of generating receptor-
targeted metal-based anticancer drugs with reduced toxic side 
effects based on dual control over selectivity. The fact that the Pt-35 
c(RGDfK) conjugate can also be internalized by αVβ5 integrin 
opens the door to delivering such promising anticancer 
metallodrugs to tumours overexpressing αVβ5 integrin13 or to 
tumours coexpressing both αVβ3 and αVβ5 integrins.7b,14 Such a 
multi-integrin targeting approach would provide new metal-based 40 
anticancer strategies and so benefit a wider range of patients by 
increasing the number of tumours which can be targeted.15  
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